Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review

被引:28
作者
Formentini, A [1 ]
Henne-Bruns, D [1 ]
Kornmann, M [1 ]
机构
[1] Univ Ulm, Dept Visceral & Transplantat Surg, D-89075 Ulm, Germany
关键词
5-FU; colon cancer; fluoropyrimidines; gastric cancer; pancreatic cancer;
D O I
10.1007/s00423-004-0510-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and aims: Many studies have been published that report an association between thymidylate synthase (TS) and response to fluoropyrimidine-based chemotherapy and the overall outcome of patients with gastrointestinal cancer. The results have given rise to the possibility that, by determination of TS levels, the physician may decide if the patient has a potential benefit from fluoropyrimidine-based treatment, similar to measurements of oestrogen receptors in breast cancer. The purpose of this review is to summarize critically the reports on TS measurement in gastrointestinal cancer, focusing on the adjuvant fluoropyrimidine treatment situation. Methods: We reviewed more than 20 studies that reported the association of TS with the clinical outcome in patients with gastrointestinal cancer who had undergone complete resection of the primary tumour only or were receiving additional adjuvant chemotherapy. Results: Patients with metastasized disease who expressed high TS levels display a low probability of responding to fluoropyrimidine-based treatment and have a poorer survival rate. Patients with high TS levels who undergo complete surgical resection of the primary tumour also have a poorer prognosis than those with tumours with low TS expression. In contrast to advanced disease and to surgery alone, patients with high TS levels appear to benefit, especially, from adjuvant fluoropyrimidine-based chemotherapy after complete primary tumour resection, while patients with low TS levels do not. Conclusion: Patients with gastrointestinal cancers that express high TS levels have a poor prognosis with regard to fluoropyrimidine-based palliative chemotherapy or complete primary tumour resection. In contrast, patients with high TS levels might benefit from adjuvant fluoropyrimidine-based treatment after primary tumour resection. However, additional prospective studies are mandatory to define the precise role of TS in adjuvant therapy.
引用
收藏
页码:405 / 413
页数:9
相关论文
共 68 条
[51]  
SANGUEDOLCE R, 1995, ANTICANCER RES, V15, P901
[52]   A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients [J].
Sargent, DJ ;
Goldberg, RM ;
Jacobson, SD ;
Macdonald, JS ;
Labianca, R ;
Haller, DG ;
Shepherd, LE ;
Seitz, JF ;
Francini, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1091-1097
[53]   Fluorouracil in colorectal cancer a tale of two drugs: Implications for biochemical modulation [J].
Sobrero, AF ;
Aschele, C ;
Bertino, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :368-381
[54]  
SPEARS CP, 1982, CANCER RES, V42, P450
[55]   Adjuvant chemoradiotherapy in gastric cancer and carcinoma of the oesophago-gastric junction [J].
Stahl, M .
ONKOLOGIE, 2004, 27 (01) :33-36
[56]  
Suda Y, 1999, ANTICANCER RES, V19, P805
[57]   Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer [J].
Sugiyama, Y ;
Kato, T ;
Nakazato, H ;
Ito, K ;
Mizuno, I ;
Kanemitsu, T ;
Matsumoto, K ;
Yamaguchi, A ;
Nakai, K ;
Inada, K ;
Tatematsu, M .
ANTI-CANCER DRUGS, 2002, 13 (09) :931-938
[58]  
Tachikawa D, 2000, ANTICANCER RES, V20, P4103
[59]   Current status of multimodality therapy for esophageal carcinoma [J].
Tak, VM ;
Naunheim, KS .
JOURNAL OF SURGICAL RESEARCH, 2004, 117 (01) :22-29
[60]   Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives [J].
Takamura, M ;
Nio, Y ;
Yamasawa, K ;
Dong, M ;
Yamaguchi, K ;
Itakura, M .
ANTI-CANCER DRUGS, 2002, 13 (01) :75-85